Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer

Martina Troiani, Manuel Colucci, Mariantonietta D’Ambrosio, Ilaria Guccini, Emiliano Pasquini, Angelica Varesi, Aurora Valdata, Simone Mosole, Ajinkya Revandkar, Giuseppe Attanasio, Andrea Rinaldi, Anna Rinaldi, Marco Bolis, Pietro Cippà and Andrea Alimonti ()
Additional contact information
Martina Troiani: Oncology Institute of Southern Switzerland (IOSI)
Manuel Colucci: Oncology Institute of Southern Switzerland (IOSI)
Mariantonietta D’Ambrosio: Oncology Institute of Southern Switzerland (IOSI)
Ilaria Guccini: ETH Zurich
Emiliano Pasquini: Oncology Institute of Southern Switzerland (IOSI)
Angelica Varesi: Oncology Institute of Southern Switzerland (IOSI)
Aurora Valdata: Oncology Institute of Southern Switzerland (IOSI)
Simone Mosole: Oncology Institute of Southern Switzerland (IOSI)
Ajinkya Revandkar: Oncology Institute of Southern Switzerland (IOSI)
Giuseppe Attanasio: Oncology Institute of Southern Switzerland (IOSI)
Andrea Rinaldi: Oncology Institute of Southern Switzerland (IOSI)
Anna Rinaldi: Ente Ospedaliero Cantonale
Marco Bolis: Oncology Institute of Southern Switzerland (IOSI)
Pietro Cippà: Ente Ospedaliero Cantonale
Andrea Alimonti: Oncology Institute of Southern Switzerland (IOSI)

Nature Communications, 2022, vol. 13, issue 1, 1-14

Abstract: Abstract Cells subjected to treatment with anti-cancer therapies can evade apoptosis through cellular senescence. Persistent senescent tumor cells remain metabolically active, possess a secretory phenotype, and can promote tumor proliferation and metastatic dissemination. Removal of senescent tumor cells (senolytic therapy) has therefore emerged as a promising therapeutic strategy. Here, using single-cell RNA-sequencing, we find that senescent tumor cells rely on the anti-apoptotic gene Mcl-1 for their survival. Mcl-1 is upregulated in senescent tumor cells, including cells expressing low levels of Bcl-2, an established target for senolytic therapy. While treatment with the Bcl-2 inhibitor Navitoclax results in the reduction of metastases in tumor bearing mice, treatment with the Mcl-1 inhibitor S63845 leads to complete elimination of senescent tumor cells and metastases. These findings provide insights on the mechanism by which senescent tumor cells survive and reveal a vulnerability that can be exploited for cancer therapy.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-29824-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-29824-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-29824-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().